Follow us on Twitter
twitter icon@FreshPatents


Gastrointestinal Diseases patents

      

This page is updated frequently with new Gastrointestinal Diseases-related patent applications.




 Substituted prolines / piperidines as orexin receptor antagonists patent thumbnailSubstituted prolines / piperidines as orexin receptor antagonists
The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..
Eolas Therapeutics, Inc.


 Piperidine compounds, pharmaceutical composition comprising the same and its use patent thumbnailPiperidine compounds, pharmaceutical composition comprising the same and its use
Piperidine compounds and pharmaceutically useful salts thereof, a pharmaceutical composition including an effective amount of the racemic or enantiomerically enriched piperidine compounds to treat gastrointestinal diseases, and a method of treating gastrointestinal diseases in a mammal are provided.. .
Sk Biopharmaceuticals Co., Ltd.


 Fluorinated arylalkylaminocarboxamide derivatives patent thumbnailFluorinated arylalkylaminocarboxamide derivatives
Fluorinated arylalkylaminocarboxamide derivatives of formula (i) are described wherein w, j, n, r1, r2, r2′, r3, r4, r5 and r6 have the meanings as defined in the specification and pharmaceutically salts thereof, pharmaceutical compositions containing them as active ingredients and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urolological, and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .
Newron Pharmaceuticals S.p.a.


 Use and identification of biomarkers for gastrointestinal diseases patent thumbnailUse and identification of biomarkers for gastrointestinal diseases
The described invention relates to the identification of biomarkers for gastrointestinal diseases and provides methods utilizing the biomarkers for in drug discovery, monitoring of treatment efficacy, and diagnostics. The invention further provides methods for identifying a therapeutic target to treat ulcerative colitis, colorectal cancer, and crohn's disease..
Alfagene Bioscience, Inc.


 Drug for disease caused by expression of periostin except eye disease, and use thereof patent thumbnailDrug for disease caused by expression of periostin except eye disease, and use thereof
The present invention is intended to provide a novel molecule that inhibits the expression of the periostin gene that is effective in treatment of diseases caused by the expression of periostin except for eye diseases. A drug for a disease caused by the expression of periostin except for an eye disease includes, as an expression inhibitory sequence for the periostin gene, a nucleic acid molecule including a nucleotide that has a base sequence represented by any one of seq id nos: 1 to 19.
Aqua Therapeutics Co., Ltd.


 Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases patent thumbnailMethods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases
Wherein d, x, y, r1, r2, r3, r4, r5, r6, r7 and r8 are as defined herein.. .

 Quinine compounds, and optical isomers, preparation method and medical use thereof patent thumbnailQuinine compounds, and optical isomers, preparation method and medical use thereof
The present invention discloses a class of quinine compounds and pharmaceutically acceptable salts, solvates, prodrugs or optical isomers thereof. Also disclosed in the present invention are that the above compounds have a selective antagonistic effect on the receptor subtypes of m1 and m3, but have no significant effect on m2 receptor subtype, and the above compounds are characterized by rapid action, long-lasting efficacy, and low toxic and side-effects when used to treat rhinitis, post-cold rhinitis, chronic trachitis, airway hyperresponsiveness, asthma, chronic obstructive pulmonary diseases, cough, urinary incontinence, frequent urination, unstable bladder syndrome, bladder spasms, bladder inflammation and gastrointestinal diseases such as irritable bowel syndrome, spastic colitis, as well as duodenal and gastric ulcers..
Beijing Fswelcome Technology Development Co., Ltd


 Compositions and methods for treatment and prophylaxis of gastrointestinal diseases patent thumbnailCompositions and methods for treatment and prophylaxis of gastrointestinal diseases
Methods and compositions for treating inflammatory bowel disease, irritable bowel syndrome, and travelers' diarrhea involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic.

 Compositions and methods patent thumbnailCompositions and methods
Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.. .
Seres Therapeutics, Inc.


 Compositions and methods patent thumbnailCompositions and methods
Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.. .

Multi-tailed lipids and uses thereof

The present invention provides multi-tailed lipid compounds, and salts and stereoisomers thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an sirna, mrna, plasmid dna, small molecule, protein, peptide).
Massachusetts Institute Of Technology

Composition for preventing and treating gastrointestinal diseases, containing essential oils extracted from litsea japonica fruit

The present invention relates to a composition for preventing and treating gastrointestinal diseases by using litsea japonica, and specifically, to a composition for preventing and treating gastrointestinal diseases, containing essential oils extracted from litsea japonica fruit as an active ingredient. According to the present invention, the essential oils extracted from litsea japonica fruits (pure fruit, seed fruit, and seeds) and used as the active ingredient of the composition for preventing and treating gastrointestinal diseases have been confirmed to have excellent effects in an efficacy evaluation for relieving gastrointestinal diseases caused by helicobacter pylori, which is a gastrointestinal disease factor, physical factors induced by stress, and chemical factors induced by indomethacin.
Jeju Technopark

Compositions and methods for the treatment of inflammatory bowel disease

The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
Cellix Bio Private Limited

Compositions and methods for the treatment of inflammatory bowel disease

The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Bicyclic derivative containing pyrimidine ring, and preparation method therefor

The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-ht4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (gerd), constipation, irritable bowel syndrome (ibs), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like..
Yuhan Corporation

Brush-poly (glycoamidoamine)-lipids and uses thereof

Which may assist the pgal and/or a complex of the pgal and an agent to pass through cell membranes or be taken up by cells. Also provided are compositions including a described pgal and an agent (e.g., polynucleotide, small molecule, peptide, or protein).

Compositions and methods for binding cysteinyl leukotrienes (cyslts) for treatment of disease

Methods are provided for using antibodies and antibody fragments that bind one or more cysteinyl leukotrienes (cyslts) for treatment of diseases, including inflammatory, respiratory and gastrointestinal diseases and conditions associated with aberrant levels of one or more cyslts. Anti-cyslt antibodies and antigen-binding antibody fragments, and compositions containing such antibodies and antibody fragments, are also provided..
Lpath, Inc.

Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation

The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation.. .
Enzymotec Ltd.

Methods, compounds, and compositions for the treatment of angiotensin-related diseases

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.. .
University Of Southern California

Polyamine-fatty acid derived lipidoids and uses thereof

The present disclosure provides polyamine-fatty acid derived lipidoids (e.g., compounds of formula (i) or (ii)) and methods of preparing the lipidoids. A described lipidoid includes r—c(═o)—o— moieties (where r is a lipid moiety), which may be hydrolyzed into non-toxic fatty acids.
Massachusetts Institute Of Technology

Hydroxyindalpine derivatives and their medical use

The present invention relates to hydroxyindalpine derivatives of formula (i) as defined herein and pharmaceutical compositions comprising these compounds, as well as their medical use, particularly in the treatment or prevention of gastrointestinal diseases/disorders, such as constipation and functional dyspepsia.. .
Technische UniversitÄt MÜnchen

Formulations of guanylate cyclase c agonists and methods of use

The invention provides novel formulations of guanylate cyclase-c(“gcc”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including gastrointestinal cancer. The gcc agonist formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cgmp-dependent phosphodiesterase or a laxative..
Synergy Pharmaceuticals, Inc.

Sesquiterpene lactone-based pharmaceutical composition for treating gastrointestinal diseases

The present invention relates to a sesquiterpene lactone-based pharmaceutical composition for treating gastrointestinal diseases. More particularly, the present invention relates to a pharmaceutical composition, containing as an active ingredient a sesquiterpene lactone-based derivative derived from parthenolide, for preventing or treating gastritis or gastric ulcers..
Cho Dang Pharm. Co., Ltd.

Sesquiterpene lactone-based pharmaceutical composition for treating gastrointestinal diseases

The present invention relates to a sesquiterpene lactone-based pharmaceutical composition for treating gastrointestinal diseases. More particularly, the present invention relates to a pharmaceutical composition, containing as an active ingredient a sesquiterpene lactone-based derivative derived from parthenolide, for preventing or treating gastritis or gastric ulcers..
Cho Dang Pharm. Co., Ltd.

Materials and methods for treating diarrhea

The present invention provides therapeutic compositions and methods for treating gastrointestinal diseases and conditions such as diarrhea, for providing rehydration, for correcting electrolyte and fluid imbalances, and/or for improving small intestine function. In one embodiment, the present invention provides a composition formulated for enteral administration, wherein the composition does not contain glucose.
University Of Florida Research Foundation, Incorporated

Sesquiterpene lactone-based pharmaceutical composition for treating gastrointestinal diseases

The present invention relates to a sesquiterpene lactone-based pharmaceutical composition for treating gastrointestinal diseases. More particularly, the present invention relates to a pharmaceutical composition, containing as an active ingredient, a sesquiterpene lactone-based derivative derived from parthenolide, for preventing or treating gastritis or gastric ulcers..

Combinations with a backbone-cyclized peptide

A novel combination comprising a β-hairpin peptidomimetic of the formula cyclo(-thr-trp-ile-dab-orn-ddab-dab-trp-dab-dab-ala-ser-dpro-pro) (i), and a further compound with antibiotic activity, that enable therapeutic control of specific bacterial infections in human or animals at doses of the individual compounds lower than either of the compounds administered alone. The combination can be used as a medicament to treat e.g.
Polyphor Ag

Combinations with a backbone-cyclized peptide

A novel combination comprising a β-hairpin peptidomimetic of the formula cyclo(-thr-trp-ile-dab-orn-ddab-dab-trp-dab-dab-ala-ser-dpro-pro) (i), and a compound of the glycylcycline class, especially tigecycline, that enable therapeutic control of specific bacterial infections in human or animals at doses of the individual compounds lower than either of the compounds administered alone. The combination can be used as a medicament to treat e.g.
Polyphor Ag

Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions

In alternative embodiments, the invention provides compositions, e.g., formulations or preparations, used for treating, ameliorating or preventing constipation and other disorders with related gastrointestinal symptoms. In alternative embodiments, the invention provides compositions, e.g., formulations or preparations, used for treating, ameliorating or preventing conditions which benefit from increasing or speeding bowel transit, including for example: cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue syndrome (cfs), bloating, proctalgia fugax, small intestinal bacterial overgrowth (sibo) and large intestinal bacterial overgrowth (libo), chronic nausea, functional dyspepsia and bloating.
Salix Pharmaceuticals, Inc.

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

X, y, z, r, r1, r2, r3, r′3 r4, r5, r6, r7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

X, y, z, r, r1, r2, r3, r′3 r4, r5, r6, r7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

X, y, z, r, r1, r2, r3, r′3 r4, r5, r6, r7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

X, y, z, r, r1, r2, r3, r′3 r4, r5, r6, r7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .

Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators

X, y, z, r, r1, r2, r3, r′3 r4, r5, r6, r7 have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .

Methods for treating gastrointestinal diseases

Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating gastrointestinal diseases.. .
Cempra Pharmaceuticals, Inc.

Compositions and methods

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.. .
Seres Health, Inc.

Method for extracting treatment ingredients for gastrointestinal diseases from bark of liriodendron tulipifera

The present invention relates to a method for extracting treatment ingredients for gastrointestinal diseases from the bark of liriodendron tulipifera, the treatment ingredients containing epitulipinolide and costunolide as active ingredients, and to a therapeutic agent for gastrointestinal diseases, containing epitulipinolide and costunolide extracted using said method.. .
Cho Dang Pharm. Co., Ltd

Pharmaceutical composition containing as active ingredient extract from bark of liriodendron tulipifera

The present invention relates to a pharmaceutical composition containing, as active ingredients, epitulipinolide and costunolide extracted from the bark of liriodendron tulipifera. More specifically, the present invention relates to a pharmaceutical composition for treating the gastrointestinal tract, the composition containing, as active ingredients, epitulipinolide and costunolide, which are the active ingredients of the extract from the bark of liriodendron tulipifera, and to the use thereof as a therapeutic agent for gastrointestinal diseases..
Cho Dang Pharm Co., Ltd.

Oil-based pharmaceutical composition for the treatment of gastrointestinal diseases

The present invention relates to a composition for oral use in the treatment of gastrointestinal pathologies comprising silicone antifoaming agents in an oily solvent medium, wherein the concentration of said silicone antifoaming agents is between 0.1% and 80% by weight.. .
Gruppo Farmaimpresa S.r.l.

Materials and methods for treating diarrhea

The present invention provides therapeutic compositions and methods for treating gastrointestinal diseases and conditions such as diarrhea, for providing rehydration, for correcting electrolyte and fluid imbalances, and/or for improving small intestine function. In one embodiment, the present invention provides a composition formulated for enteral administration, wherein the composition does not contain glucose.
University Of Florida Research Foundation, Inc.

Biphenylcarboxamides as rock kinase inhibitors

The present invention relates to new kinase inhibitors, more specifically rock inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new rock inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.
Amakem Nv

Substituted prolines / piperidines as orexin receptor antagonists

The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..

Substituted prolines / piperidines as orexin receptor antagonists

The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..

Compositions and methods

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.. .

Methods and treatment for allergies and inflammation associated with gastrointestinal diseases

Methods of the prophylaxis of the development of allergy in a patient at risk of sensitization to an antigen(s) or allergen(s) due to impaired gastrointestinal functions include administering a mast cell inhibitor, e.g., ketotifen, e.g., ketotifen fumarate. Methods for prophylactically treating, reducing, delaying or controlling gastrointestinal disorders include administering a mast cell stabilizer, e.g., ketotifen to a patient in need thereof.

Methylpiperidine derivative

A compound represented by formula (ia) or a pharmaceutically acceptable salt thereof, which acts relying on an orexin (ox) receptor antagonistic activity and is useful for the treatment or prevention of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, head ache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases and hypertension.. .

Method for treating diabetes with extended release formulation of glp-1 receptor agonists

The disclosure provides methods for treating diabetes, treating overweight, treating obesity, reducing body weight, treating cardiovascular diseases, treating fatty liver diseases, treating gastrointestinal diseases, and treating neurodegenerative diseases through the once monthly administration of pharmaceutical formulations containing a non-aqueous carrier and glp-1 receptor agonists that provides therapeutically effective plasma concentration levels of the glp-1 receptor agonists over the course of a month.. .

Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation

The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation.. .

Piperidine compounds, pharmaceutical composition comprising the same and its use

Piperidine compounds and pharmaceutically useful salts thereof, a pharmaceutical composition including an effective amount of the racemic or enantiomerically enriched piperidine compounds to treat gastrointestinal diseases, and a method of treating gastrointestinal diseases in a mammal are provided.. .

Fluorinated arylalkylaminocarboxamide derivatives

Fluorinated arylalkylaminocarboxamide derivatives of formula (i) are described wherein w, j, n, r1, r2, r3, r4, r5 and r6 have the meanings as defined in the specification and pharmaceutically salts thereof, pharmaceutical compositions containing them as active ingredients and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urological, and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .



Gastrointestinal Diseases topics:
  • Gastrointestinal Diseases
  • Gastrointestinal
  • Intestinal Diseases
  • Gastrointestinal Disease
  • Pharmaceutically Acceptable Salt
  • Pharmaceutically Acceptable Salts
  • Urogenital
  • Neurological
  • Pathologic
  • Psychiatric
  • Inflammation
  • Schizophrenia
  • Sleep Disorder
  • Eating Disorder
  • Panic Disorder


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Gastrointestinal Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Gastrointestinal Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4623

    file did exist - 3108

    1 - 1 - 51